

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
24 June 2021 (24.06.2021)



(10) International Publication Number  
**WO 2021/126672 A1**

(51) International Patent Classification:

A61K 38/19 (2006.01) A61K 39/00 (2006.01)  
A61K 38/20 (2006.01) A61K 39/395 (2006.01)

(21) International Application Number:

PCT/US2020/064415

(22) International Filing Date:

11 December 2020 (11.12.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/951,309 20 December 2019 (20.12.2019) US

(71) Applicant: **MEDIMMUNE, LLC** [US/US]; One Medimmune Way, Gaithersburg, MD 20878 (US).

(72) Inventors: **GILBRETH, Ryan**; C/O MEDIMMUNE, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US). **MOODY, Gordon**; C/O MEDIMMUNE, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US). **GIARDINO TORCHIA, Maria, Letizia**; C/O MEDIMMUNE, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US). **WANG, Qiong**; C/O MEDIMMUNE, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US).

**MUMM, John**; C/O MEDIMMUNE, LLC, One Medimmune Way, Gaithersburg, MD 20878 (US).

(74) Agent: **CONOUR, John E.** et al.; McDonnell Boehnen Hulbert & Berghoff LLP, 300 South Wacker Drive, Chicago, Illinois 60606 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: COMPOSITIONS AND METHODS OF TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN 3

HCC  
(n=49)



NSCLC SCC  
(n=76)



Ovarian clear cell  
(n=15)



| % Positive (n)<br>at any intensity | % High Pos. (n)<br>>2+ in 50% of TC |
|------------------------------------|-------------------------------------|
| 80% (39)                           | 33% (16)                            |
| 30% (23)                           | 7% (5)                              |
| 47% (7)                            | 20% (3)                             |

Figure 1A

(57) Abstract: This disclosure relates to compositions and methods for treating cancer using chimeric antigen receptor T cells targeting glypican 3.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*